It would be attractive to further validate these findings in prospective serial rebiopsy study in EGFR-mutant patients under EGFR-TKI therapy, including the early time-window in the midst of tumor response (1st week to 1-2 months post-therapy), using comprehensive transcriptomic profiling analysis [43]. Here, EGFR is linked to neoplasm.